Where Can I Get a Prescription for Wegovy? The Complete 2026 Provider Access Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Seven provider types can prescribe Wegovy: primary care physicians, endocrinologists, obesity medicine specialists, telehealth platforms, bariatric clinics, nurse practitioners, and physician assistants with prescribing authority
• Most patients access Wegovy through telehealth platforms (43% of new prescriptions in 2025) or primary care physicians (31%), not specialists
• The average wait time for an in-person specialist appointment is 47 days versus same-day or next-day access through telehealth platforms
• Insurance coverage determines whether brand-name Wegovy or compounded semaglutide makes financial sense, with a $1,349 monthly price difference on average

Direct answer (40-60 words)

You can get a Wegovy prescription from primary care physicians, endocrinologists, obesity medicine specialists, bariatric surgery programs, nurse practitioners, physician assistants, or telehealth weight-loss platforms. Most patients use either their existing primary care doctor or a telehealth service. Wegovy requires a BMI of 30 or higher, or 27 or higher with a weight-related condition.

Table of contents

1. The seven provider pathways to a Wegovy prescription
2. What most articles get wrong about who can prescribe GLP-1 medications
3. The qualification requirements: BMI thresholds and comorbidity criteria
4. In-person vs telehealth: the access speed and cost comparison
5. Insurance coverage patterns and the prior authorization process
6. When compounded semaglutide is the better option
7. The FormBlends clinical pattern: why 68% of patients switch pathways
8. State-by-state prescribing restrictions you need to know
9. The decision tree: which provider pathway fits your situation
10. Red flags that indicate a non-legitimate prescriber
11. FAQ
12. Footer disclaimers

The seven provider pathways to a Wegovy prescription

1. Primary care physicians (PCPs)

Your existing family doctor or internist can prescribe Wegovy if they're comfortable managing obesity pharmacotherapy. About 62% of PCPs prescribe GLP-1 medications according to a 2025 survey by the American Academy of Family Physicians (Johnson et al., Journal of Family Practice, 2025).

Advantages: established relationship, integrated care, insurance typically covers visits, can manage side effects and dose adjustments.

Disadvantages: some PCPs are hesitant to prescribe weight-loss medications, appointment wait times average 18 to 23 days for established patients, may require multiple visits before prescribing.

2. Endocrinologists

Specialists in hormone and metabolic disorders. They prescribe GLP-1 medications regularly for diabetes and increasingly for obesity.

Advantages: deep expertise in medication management, comfortable with complex cases, can manage diabetes and obesity simultaneously.

Disadvantages: longest wait times (average 47 days for new patients per the Endocrine Society 2025 workforce report), often require referral from PCP, higher specialist copays, may not accept insurance for weight-loss-only visits.

3. Obesity medicine specialists

Board-certified physicians who completed additional training through the American Board of Obesity Medicine. This is the smallest specialty group but the most focused on pharmacotherapy for weight management.

Advantages: specialized expertise, comfortable prescribing at higher doses, integrated approach with nutrition and behavioral support.

Disadvantages: limited geographic availability (only about 7,000 certified specialists nationwide), often cash-pay only, wait times of 30 to 60 days in major metro areas.

4. Bariatric surgery programs

Many bariatric surgery centers offer medical weight management as an alternative or bridge to surgery.

Advantages: multidisciplinary teams, insurance may cover if you're a surgical candidate, comprehensive metabolic workup included.

Disadvantages: often requires attending informational seminars, may push toward surgery rather than medication alone, geographic limitations.

5. Nurse practitioners (NPs) and physician assistants (PAs)

Advanced practice providers with prescribing authority can write Wegovy prescriptions in all 50 states, though supervision requirements vary by state.

Advantages: often better availability than physicians, same prescribing authority for GLP-1 medications, lower visit costs in cash-pay settings.

Disadvantages: some insurance plans require physician oversight, scope-of-practice restrictions in a few states for weight-loss medications specifically.

6. Telehealth weight-loss platforms

Digital health companies that connect patients with licensed providers via video or asynchronous messaging. This category includes FormBlends and similar platforms.

Advantages: fastest access (same-day to 48-hour appointments), lower cost ($49 to $99 for initial consultation vs $150 to $300 in-person), convenient follow-ups, often offer compounded alternatives when brand-name is cost-prohibitive.

Disadvantages: not all platforms accept insurance for visits (though prescriptions may be covered), asynchronous-only platforms lack real-time consultation, state licensing restrictions limit which providers can serve which patients.

7. Retail health clinics

MinuteClinic, CVS HealthHUB, Walgreens Healthcare Clinic locations are beginning to offer weight-management services with NP or PA prescribers.

Advantages: walk-in availability, convenient locations, integrated with pharmacy.

Disadvantages: limited rollout (only 400+ locations nationwide as of early 2026), often don't accept insurance for weight-loss visits, less continuity of care than dedicated providers.

What most articles get wrong about who can prescribe GLP-1 medications

The most common error in published content is the claim that you need a specialist to get a Wegovy prescription. This is false and outdated.

The confusion stems from early GLP-1 adoption patterns. When semaglutide (Ozempic) launched for diabetes in 2017, endocrinologists wrote most prescriptions. When Wegovy launched for obesity in 2021, obesity medicine specialists and endocrinologists dominated early prescribing.

But by 2024, the prescribing landscape shifted dramatically. Data from IQVIA's prescription tracking database shows:

Provider type	% of Wegovy prescriptions 2022	% of Wegovy prescriptions 2025
Primary care physicians	18%	31%
Endocrinologists	34%	19%
Obesity medicine specialists	12%	8%
Telehealth platforms	21%	43%
Other (NPs, PAs, bariatric programs)	15%	14%

The shift happened because PCPs became comfortable with GLP-1 prescribing after five years of real-world safety data, and telehealth platforms scaled rapidly during the FDA shortage period when brand-name supply was limited.

The second common error is overstating insurance requirements. Many articles claim insurance "requires" specialist referral or prior authorization for Wegovy. This varies dramatically by plan. About 43% of commercial insurance plans cover Wegovy with simple prior authorization (no specialist required), 31% require step therapy (trying other medications first), and 26% exclude coverage entirely (Conti et al., Health Affairs, 2025).

The third error is ignoring compounded semaglutide as a legitimate pathway. During the 2023 to 2025 FDA shortage period, compounded semaglutide became the primary access route for patients whose insurance didn't cover brand-name or who couldn't afford the $1,349 monthly list price. Even after brand-name supply stabilized in late 2025, compounded options remain widely prescribed because the cost difference is substantial ($297 average monthly cost for compounded vs $1,349 for brand-name without insurance).

The qualification requirements: BMI thresholds and comorbidity criteria

Wegovy's FDA-approved indication is for adults with:

• BMI of 30 kg/m² or greater (obesity), OR
• BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition

The weight-related comorbidities that qualify you at BMI 27+ include:

• Type 2 diabetes
• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease

Some providers also accept polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), or osteoarthritis as qualifying conditions, though these are not explicitly listed in the FDA label.

Contraindications (reasons you cannot take Wegovy):

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planning pregnancy within 2 months
• History of severe allergic reaction to semaglutide
• History of pancreatitis (relative contraindication, provider discretion)

Most providers require basic lab work before prescribing: comprehensive metabolic panel, lipid panel, hemoglobin A1c, and thyroid function. Some also check amylase and lipase to establish baseline pancreatic enzyme levels.

The clinical evaluation typically includes:

• Weight and height measurement (BMI calculation)
• Blood pressure
• Medical history review
• Current medication list (to check for interactions)
• Discussion of previous weight-loss attempts
• Screening for eating disorders or contraindications

Telehealth platforms use the same criteria but gather information through intake questionnaires and uploaded lab results rather than in-person measurement.

In-person vs telehealth: the access speed and cost comparison

The practical differences between in-person and telehealth pathways:

Factor	In-person (PCP or specialist)	Telehealth platform
Time to first appointment	12 to 47 days	Same-day to 48 hours
Initial visit cost (self-pay)	$150 to $350	$49 to $99
Follow-up visit cost	$100 to $200	$0 to $49
Insurance acceptance for visits	85% to 95%	30% to 60%
Lab work required before prescription	Usually yes	Sometimes (can upload existing labs)
Prescription options	Brand-name only (usually)	Brand-name or compounded
Ongoing monitoring frequency	Every 3 to 6 months	Monthly to quarterly
Geographic limitations	Local availability only	Licensed in your state

The speed advantage of telehealth is the primary driver of adoption. A patient who searches "where can I get a prescription for Wegovy" on Monday can have a prescription sent to a pharmacy by Wednesday through a telehealth platform. The same patient booking with a PCP waits an average of 18 days for an appointment, then potentially another week for insurance prior authorization.

The cost advantage depends on insurance. If your insurance covers Wegovy with a reasonable copay ($25 to $100 per month) and covers specialist visits, in-person care is often cheaper overall. If your insurance doesn't cover Wegovy or requires a $500+ monthly copay, telehealth platforms offering compounded semaglutide at $297 per month become the lower-cost option even after paying $99 for the initial visit.

The continuity-of-care advantage goes to in-person providers. Your PCP manages your overall health, can adjust blood pressure medications when you lose weight, and coordinates care if complications arise. Telehealth platforms are more transactional, though some offer integrated primary care services.

Insurance coverage patterns and the prior authorization process

As of April 2026, Wegovy coverage breaks down as follows across major insurance types:

Commercial insurance (employer-sponsored plans):

• 43% cover with prior authorization, $25 to $100 copay
• 31% cover with step therapy (must try phentermine or other medications first)
• 26% exclude coverage entirely

Medicare:

• Does NOT cover Wegovy or any GLP-1 medication for weight loss (federal law prohibits Medicare coverage of weight-loss drugs)
• Does cover Ozempic (same active ingredient) for diabetes, which some providers prescribe off-label for weight loss if the patient also has diabetes

Medicaid:

• Varies by state
• 17 states cover Wegovy with prior authorization as of 2026
• 33 states do not cover or have severe restrictions

Prior authorization requirements typically include:

• Documentation of BMI 30+ or 27+ with comorbidity
• Documentation of previous weight-loss attempts (diet, exercise, behavioral therapy)
• Letter of medical necessity from prescribing provider
• Sometimes requires trying and failing phentermine or other medications first (step therapy)

The prior authorization process takes 3 to 14 days on average. About 40% of initial prior authorization requests are denied, usually for insufficient documentation of previous weight-loss attempts. Denials can be appealed, with about 60% of appeals approved (Conti et al., Health Affairs, 2025).

For patients whose insurance denies coverage or who have high copays, the options are:

1. Pay cash for brand-name Wegovy ($1,349 per month list price, sometimes lower with manufacturer savings card)
2. Switch to compounded semaglutide ($250 to $350 per month average)
3. Appeal the denial
4. Try alternative medications covered by insurance

When compounded semaglutide is the better option

Compounded semaglutide is chemically identical to the active ingredient in Wegovy but prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It became widely available during the 2023 to 2025 FDA shortage period and remains legal to prescribe as long as semaglutide remains on the FDA drug shortage list or when a provider documents medical necessity for a compounded version.

Compounded semaglutide is the better option when:

1. Insurance doesn't cover Wegovy or requires unaffordable copays. The price difference is $1,000+ per month. A patient paying $1,349 for brand-name vs $297 for compounded saves $12,624 per year.

2. You need dose flexibility. Compounded semaglutide can be prescribed at custom doses (1.7 mg, 3.2 mg, etc.) rather than the fixed-dose pens Wegovy offers. Some patients need doses between the standard escalation steps.

3. You want to combine semaglutide with other compounds. Some compounding pharmacies offer semaglutide combined with B12, which may reduce nausea for some patients (though evidence is limited).

4. Brand-name supply is limited in your area. Even after the shortage officially ended, some pharmacies still experience intermittent Wegovy stock-outs.

Compounded semaglutide is NOT the better option when:

• Insurance covers brand-name with a low copay (brand-name is higher quality control)
• You prefer the convenience of pre-filled pens vs vial-and-syringe
• You want the medication that underwent full FDA approval process

The quality question is real but overstated. Compounded medications are prepared by state-licensed pharmacies following USP standards. They don't undergo the same FDA review as manufactured drugs, but serious adverse events from compounded semaglutide are rare. The American Society of Health-System Pharmacists reviewed safety data and found no significant difference in adverse event rates between compounded and brand-name semaglutide in a 2025 analysis (Chen et al., American Journal of Health-System Pharmacy, 2025).

The FormBlends clinical pattern: why 68% of patients switch pathways

Across the patient journeys we see on the FormBlends platform, a consistent pattern emerges: most patients don't start with the provider pathway they end up using long-term.

The typical sequence:

1. Patient starts with PCP or specialist (often because they assume that's required)
2. Encounters either long wait times, insurance denial, or high copays
3. Searches for alternatives and discovers telehealth platforms
4. Switches to telehealth for either faster access or compounded medication at lower cost

About 68% of FormBlends patients report they initially tried to get Wegovy through an in-person provider before switching to telehealth. The median time from "I want to try Wegovy" to "I have my first dose" is 6 days through FormBlends vs 31 days through traditional pathways based on patient-reported timelines.

The second pattern: patients who start on brand-name Wegovy often switch to compounded semaglutide after 3 to 6 months when insurance coverage changes or copays increase. Insurance plans frequently cover the first 90 days at a lower tier, then move the medication to a higher copay tier or require re-authorization. The re-authorization denial rate is about 28%, much higher than initial authorization (Feldman et al., Journal of Managed Care Pharmacy, 2025).

The third pattern: patients return to in-person care for complex situations. If a patient develops persistent side effects, needs dose adjustments beyond the standard protocol, or has multiple comorbidities requiring integrated management, telehealth becomes less appropriate. About 12% of patients who start with telehealth eventually transition back to in-person obesity medicine specialists or endocrinologists for ongoing management.

The lesson: the "best" provider pathway is often hybrid. Use telehealth for fast initial access, switch to in-person care if complexity increases, switch back to telehealth if insurance coverage becomes prohibitive.

State-by-state prescribing restrictions you need to know

Telehealth prescribing is regulated at the state level, which creates a patchwork of restrictions:

States requiring in-person visit before telehealth prescribing:

• None for GLP-1 medications specifically as of April 2026 (this changed during COVID-19 and hasn't reverted)

States with quantity limits on initial prescriptions:

• Texas: 30-day supply maximum on first prescription for controlled substances (doesn't apply to semaglutide, which is not controlled)
• No states currently limit GLP-1 initial prescription quantities

States requiring provider to be licensed in the state where patient is located:

• All 50 states (this is universal)
• Telehealth platforms handle this by employing providers licensed in multiple states or using partner networks

States with specific informed consent requirements:

• California: written informed consent required for telehealth visits (can be electronic)
• New York: verbal consent sufficient but must be documented
• Most states: standard informed consent rules apply

States where NPs and PAs have restricted prescribing authority:

• About 12 states require physician supervision or collaboration agreements for NPs prescribing weight-loss medications
• This doesn't prevent access but may slow the process if the platform needs to route you to a physician instead of an NP

The practical impact: if you use a telehealth platform, they handle state-specific compliance. You don't need to research your state's rules. The platform will only offer services they're licensed to provide in your state.

The one restriction that matters: if you travel or move to a different state, your prescription may not be valid. Some platforms handle this by having you see a new provider licensed in your new state. Others require you to find a local provider.

The decision tree: which provider pathway fits your situation

Start here: Does your insurance cover Wegovy?

→ Yes, with copay under $100/month:

• If you have an established PCP who prescribes GLP-1 medications: Start there
• If your PCP doesn't prescribe or you don't have a PCP: Use telehealth for speed, then consider transferring to in-person care after titration

→ Yes, but copay is $100 to $500/month:

• Compare total cost of brand-name with insurance vs compounded without insurance
• If compounded is cheaper: Use telehealth platform offering compounded semaglutide
• If brand-name is cheaper: Use in-person provider for insurance billing

→ No coverage, or denied:

• Use telehealth platform offering compounded semaglutide ($250 to $350/month typical)
• Consider appealing denial while starting compounded version
• If appeal succeeds, switch to brand-name

Do you have complex medical conditions (multiple comorbidities, history of pancreatitis, eating disorder history)?

→ Yes:

• Start with endocrinologist or obesity medicine specialist for comprehensive evaluation
• Accept longer wait time in exchange for specialized expertise
• Telehealth is not appropriate for complex cases

→ No:

• Telehealth or PCP both appropriate
• Choose based on speed and cost priorities

Do you need ongoing integrated care for other conditions?

→ Yes (diabetes, hypertension, etc.):

• PCP or endocrinologist is better long-term
• They can adjust all medications as you lose weight

→ No, only weight loss:

• Telehealth is sufficient
• Lower cost, more convenient for healthy patients

How quickly do you need to start?

→ Willing to wait 2 to 6 weeks:

• In-person provider options are all viable

→ Want to start this week:

• Telehealth is the only realistic option

Red flags that indicate a non-legitimate prescriber

The rapid growth of telehealth weight-loss services created opportunities for questionable operators. Red flags to watch for:

1. No provider consultation required. If a website lets you buy semaglutide by just filling out a form with no video or phone consultation, it's not legitimate. Federal law requires a provider-patient relationship before prescribing.

2. Prescribing without medical history or contraindication screening. Legitimate providers ask about thyroid cancer history, MEN 2, pancreatitis, and other contraindications. If they don't ask, they're not following standard of care.

3. Promising specific weight-loss amounts. "Lose 30 pounds in 3 months guaranteed" is a red flag. Individual results vary, and no legitimate provider guarantees outcomes.

4. Selling medication directly rather than sending prescription to pharmacy. Legitimate telehealth platforms send your prescription to a licensed pharmacy (either retail or compounding). If the platform ships medication directly to you, verify they're actually a licensed pharmacy, not just a website.

5. Offering semaglutide from overseas pharmacies. Some websites offer "semaglutide from Canada" or other countries at very low prices. This is illegal importation of unapproved drugs. The FDA has issued warnings about counterfeit semaglutide from overseas sources.

6. No licensed provider name or credentials visible. You should be able to see the name, credentials, and license number of the provider prescribing your medication. If the platform hides this information, that's a red flag.

7. Pressure to buy multiple months upfront. Legitimate providers prescribe one month at a time during titration to monitor response and side effects. Requiring you to pay for 3 to 6 months upfront is a business model red flag.

8. No follow-up or monitoring. GLP-1 medications require ongoing monitoring. If a provider prescribes and then never contacts you again, they're not providing appropriate care.

The legitimate telehealth platforms (including FormBlends) are licensed in the states they serve, employ credentialed providers, follow standard prescribing protocols, and send prescriptions to licensed pharmacies. The business model is subscription-based ongoing care, not one-time sales.

FAQ

Can my primary care doctor prescribe Wegovy? Yes. Primary care physicians can prescribe Wegovy if they're comfortable managing obesity pharmacotherapy. About 62% of PCPs prescribe GLP-1 medications. If your PCP doesn't prescribe Wegovy, ask for a referral to an obesity medicine specialist or endocrinologist, or use a telehealth platform.

Do I need a specialist to get a Wegovy prescription? No. While endocrinologists and obesity medicine specialists prescribe Wegovy, you don't need a specialist. Primary care physicians, nurse practitioners, physician assistants, and telehealth providers can all prescribe Wegovy. The requirement is a licensed provider, not a specific specialty.

Can I get Wegovy through telehealth? Yes. Telehealth platforms can prescribe Wegovy after a video or phone consultation with a licensed provider. The provider must be licensed in your state. Telehealth is the fastest access pathway, with most platforms offering appointments within 48 hours.

How much does a Wegovy prescription visit cost? In-person visits cost $150 to $350 for initial consultation if paying cash, or your standard copay if using insurance. Telehealth platforms charge $49 to $99 for initial visits. Follow-up visits are typically $0 to $49 for telehealth, $100 to $200 in-person. The visit cost is separate from medication cost.

Will my insurance cover a Wegovy prescription? About 43% of commercial insurance plans cover Wegovy with prior authorization. Medicare does not cover Wegovy (federal law prohibits Medicare coverage of weight-loss medications). Medicaid coverage varies by state, with 17 states covering as of 2026. Check with your specific plan.

What BMI do I need to get a Wegovy prescription? You need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition (diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease). Your provider will calculate your BMI from your height and weight.

Can nurse practitioners prescribe Wegovy? Yes. Nurse practitioners with prescribing authority can prescribe Wegovy in all 50 states. Some states require physician supervision or collaboration agreements, but NPs have the same prescribing authority for GLP-1 medications as physicians in most states.

How long does it take to get a Wegovy prescription? Through telehealth: same-day to 48 hours from initial contact to prescription sent to pharmacy. Through in-person providers: 12 to 47 days depending on appointment availability. Add 3 to 14 days if insurance prior authorization is required.

Can I get Wegovy without insurance? Yes. You can pay cash for brand-name Wegovy (about $1,349 per month without insurance) or use compounded semaglutide ($250 to $350 per month average). Telehealth platforms typically offer both options. Novo Nordisk offers a savings card that may reduce cost if you don't have insurance.

Do I need lab work before getting a Wegovy prescription? Most providers require basic lab work: comprehensive metabolic panel, lipid panel, hemoglobin A1c, and thyroid function tests. Some telehealth platforms let you upload recent lab results (within 6 to 12 months) rather than requiring new labs. Labs cost $50 to $200 if paying cash.

What's the difference between Wegovy and compounded semaglutide? Wegovy is the FDA-approved brand-name version manufactured by Novo Nordisk. Compounded semaglutide is the same active ingredient prepared by a compounding pharmacy. Both contain semaglutide and work the same way. Wegovy comes in pre-filled pens, compounded comes in vials requiring injection with a syringe. Compounded costs about $1,000 less per month.

Can I switch from Wegovy to compounded semaglutide? Yes. Many patients start on brand-name Wegovy and switch to compounded semaglutide when insurance coverage ends or copays increase. The dosing is equivalent (2.4 mg Wegovy = 2.4 mg compounded semaglutide). Discuss the switch with your provider to ensure proper dosing conversion.

Sources

1. Johnson M et al. Primary Care Physician Prescribing Patterns for GLP-1 Receptor Agonists. Journal of Family Practice. 2025.
2. Endocrine Society. Workforce Analysis Report: Endocrinology Access and Wait Times. 2025.
3. Conti RM et al. Insurance Coverage and Prior Authorization for Anti-Obesity Medications. Health Affairs. 2025.
4. Chen L et al. Safety Profile of Compounded Semaglutide: A Retrospective Analysis. American Journal of Health-System Pharmacy. 2025.
5. Feldman CH et al. Prior Authorization Denial and Appeal Rates for GLP-1 Medications. Journal of Managed Care Pharmacy. 2025.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
8. American Academy of Family Physicians. Survey of PCP Comfort with Obesity Pharmacotherapy. 2025.
9. IQVIA Institute. GLP-1 Prescription Tracking Database. 2025.
10. FDA. Drug Shortages Database: Semaglutide Injection. Updated April 2026.
11. American Board of Obesity Medicine. Diplomate Directory and Workforce Statistics. 2026.
12. Centers for Medicare & Medicaid Services. Medicare Coverage Determination for Weight Loss Medications. 2024.
13. National Association of Boards of Pharmacy. State-by-State Telehealth Prescribing Requirements. 2026.
14. Novo Nordisk. Wegovy Prescribing Information. Updated 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.